S&P Futures
4,048.25 -36.00 (-0.88%) Dow Futures
33,840.00 -206.00 (-0.61%) Nasdaq Futures
12,072.75 -149.50 (-1.22%) Russell 2000 Futures
1,901.60 -17.90 (-0.93%) Crude Oil
79.47 -0.21 (-0.26%) Gold
1,941.30 -4.30 (-0.22%)
Curative Biotechnology, Inc. (CUBT)
Chart Events
Performance Outlook
| Previous Close | 0.0225 |
| Open | 0.0221 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0190 - 0.0270 |
| 52 Week Range | 0.0016 - 0.0800 |
| Volume | |
| Avg. Volume | 461,407 |
| Market Cap | 14.254M |
| Beta (5Y Monthly) | 300.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Paul Michaels, Chairman and President of Curative Biotechnology, said,
- GlobeNewswire
Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange
Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it intends to offer shares of its common stock for sale in an underwritten public offering, after giving effect to the Company’s proposed 1-for-400 reverse stock split. In addition, the Company expects to grant the underwriter a 45-day option to pu
- GlobeNewswire
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors
Appointment of Independent Director Builds Upon Biotech Expertise Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc. (https://biotheryx.com
